Results 201 to 210 of about 80,577 (303)
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes +7 more
wiley +1 more source
Summary Background and objectives Trust in therapy impacts adherence and satisfaction in chronic inflammatory skin diseases, including atopic dermatitis (AD) and psoriasis (PSO). This study assessed and compared trust in skincare and topical therapies and explored influencing factors among AD and PSO patients.
Svenja Royeck +9 more
wiley +1 more source
Incidence of interstitial lung disease in seropositive rheumatoid arthritis patients receiving biologics, Janus kinase inhibitors, or methotrexate. [PDF]
Yoon J +5 more
europepmc +1 more source
The emerging role of the Hippo signaling pathway in interorgan crosstalk
Hippo signaling functions as a central hub of interorgan communication. Systemic cues from the gut, adipose tissue, and skeletal muscle—including hormones, metabolites, and microbial signals—regulate YAP/TAZ activity in a tissue‐ and context‐dependent manner.
Gahyeon Song +2 more
wiley +1 more source
The use of Janus kinase inhibitors to treat noninfectious uveitis. [PDF]
Beckman M +5 more
europepmc +1 more source
Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture +3 more
wiley +1 more source
Selective Janus kinase inhibitors exhibit different effects in murine immune aplastic anemia. [PDF]
Durrani J +10 more
europepmc +1 more source
GWAS of Second‐Generation Antihistamine Use: Locus Specificity and Highlighted Signalling Pathways
Clinical &Experimental Allergy, EarlyView.
M. Niemi +15 more
wiley +1 more source
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo +11 more
wiley +1 more source

